The pharmaceutical giant said it would reduce the cost of its hepatitis C medication Zepatier by 60%.
Amid scrutiny over big pharma drug pricing, Merck said on Thursday it would lower the price of some of its medications.
"We recently priced.Hemlibra at less than half the cost of the standard treatment for hemophilia A with inhibitors", Roche said in its statement, adding that what was really needed were "long-term, system-wide solutions that lower costs, while sustaining scientific innovation".
However the price cut may also be motivated by the increasingly competitive hepatitis C drug market - sales of Zepatier slumped in the last quarter.
As for the other six products that Merck said it would take a haircut on, the products are so insignificant that Merck does not even break out sales of the drugs in its Securities and Exchange Commission filings.
Other Merck drugs, which the company hasn't yet named, will be lowered by 10%.
While that sounds like a substantial commitment, Evercore ISI analyst Umer Raffat noted that it does not amount to a significant change and "technically leaves the room open for increases where it would like to".
Several major pharmaceutical companies lowered their spending on lobbyists in the second quarter of 2018, a time of uncertainty as President Donald Trump's administration continued its campaign to lower drug costs for consumers.
Pfizer moved on July 1 to raise the prices on 41 drug products. Trump has promised to pressure the industry to lower drug prices.
"Merck (NYSE:MRK), known as MSD outside the United States and Canada, has a long history of responsible pricing".
Germany's Bayer said it had also told USA health ministry officials that it will not raise prices this year.
According to the company, some of the factors considered when choosing which products to reduce in price were the "gap between list price and actual discounted prices paid in the market, the contractual obligations under existing arrangements with payers, and the opportunity to broaden access to treatment".